BSTG
Biostage, Inc.
Set alert
4.03 0.00 0.00%
4.00 Day range 4.14
52-week range unavailable
- Open
- 4.09
- Prev close
- 4.03
- Mkt cap
- 3.03M
- Vol
- 4.53K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.00
- High
- 4.14
- Forward P/E
- -0.22
- Beta
- -0.82
- Short ratio
- 3.17
- Inst. own
- 13.65%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 12, 2023
- 50-d avg
- 0.198886
- 200-d avg
- 0.324493
- 1y target
- 3.00
Key statistics
- Market cap
- 3.03M
- Enterprise value
- -426.09K
- Trailing P/E
- -0.14
- Forward P/E
- -0.22
- PEG ratio
- 0.00
- Price / sales
- 56.17
- Price / book
- 2.29
- EPS (TTM)
- -0.562
- Beta
- -0.82
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 54.00K
- Revenue growth
- 0.00%
- Free cash flow
- -5.73M
- Total cash
- 3.42M
- Total debt
- 0
- Return on equity
- -316.10%
- Shares outstanding
- 39.03M
- Short % of float
- 8.83%
- 50-day average
- 0.198886
- 200-day average
- 0.324493
Analyst view
Consensus: hold
Hold
Price target (mean) 3.00
Next earnings
May 12, 2023
Expected May 12, 2023. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 12, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| Mar 30, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | 0.00 | — | — | — |
| Aug 4, 2022 | Jun 1, 2022 | 0.00 | — | — | — |
| May 16, 2022 | Mar 1, 2022 | 0.00 | — | — | — |
| Apr 1, 2022 | Dec 1, 2021 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 9, 2016 | Maxim Group | down | Buy | Hold |
About Biostage, Inc.
Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The companys Cellframe technology combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan organ implants. It is developing bioengineered organ implants, which addresses the damage of the esophagus, bronchus, and trachea due to cancer, infection, trauma, or congenital abnormalities. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- biostage.com
News
- Contrasting Defiance Daily Target 2X Long LMND ETF (NASDAQ:LMNX) & Biostage (OTCMKTS:BSTG)
- Financial Analysis: Biostage (OTCMKTS:BSTG) and T2 Biosystems (NASDAQ:TTOO)
- Critical Comparison: Arch Therapeutics (OTCMKTS:ARTH) vs. Biostage (OTCMKTS:BSTG)
- Biostage Activated Mayo Clinic as The First Site for Clinical Trial in Severe Esophageal Disease
- Biostage Selects IQVIA to Manage its FDA-Approved Clinical Trial in Severe Esophageal Disease, including Cancer
- Biostage, Inc. (BSTG) Q3 2022 Earnings Call Transcript
- Biostage Schedules Conference Call and Webcast for Q2 2022 Results
- Biostage Begins U.S. Uplisting IPO Rollout
- Biostage, Inc. (BSTG) Interim CEO David Green on Q1 2022 Results - Earnings Call Transcript
- Biostage Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2021 Financial Results
Your note
Sign in to keep a note on BSTG — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CANEPA JOHN J | Director | Purchase | May 24, 2016 | 17,241 |
| DERSIMONIAN HAROUT | Officer | Purchase | Oct 11, 2016 | 10,000 |
| KENNEDY JOHN F | Director | Purchase | Aug 25, 2016 | 58,406 |
| LAFRANCESCA SAVERIO | Officer | Purchase | Aug 23, 2017 | 293,998 |
| MCGORRY JAMES JOSEPH | Officer | Purchase | Aug 24, 2016 | 126,300 |
| MCNAUGHTON THOMAS | Officer | Purchase | May 19, 2016 | 206,128 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group, Inc. (The) | 1.94% | 773,820 | 292.50K | Jun 29, 2017 |
| Renaissance Technologies, LLC | 1.77% | 703,600 | 265.96K | Jun 29, 2017 |
| Blackrock Inc. | 1.53% | 608,331 | 229.95K | Jun 29, 2017 |
| PanAgora Asset Management, Inc. | 0.65% | 257,455 | 97.32K | Jun 29, 2017 |
| State of New Jersey Common Pension Fund D | 0.26% | 105,000 | 33.60K | Sep 29, 2017 |
| CALPERS (California-Public Employees Retirement System) | 0.16% | 64,800 | 24.49K | Jun 29, 2017 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.97% | 385,770 | 129.62K | Mar 30, 2017 |
| Vanguard Total Stock Market Index Fund | 0.88% | 348,844 | 117.21K | Mar 30, 2017 |
| Fidelity Extended Market Index Fund | 0.06% | 22,493 | 8.50K | Jun 29, 2017 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.02% | 6,294 | 2.38K | Jun 29, 2017 |
| Quantitative Master Series Tr-Extended Market Index Series | 0.01% | 3,656 | 1.23K | Mar 30, 2017 |
| Fidelity Total Market Index Fund | 0.01% | 3,080 | 1.16K | Jun 29, 2017 |